The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Acomplia     5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)...

Synonyms: Rimoslim, Riobant, Slimona, Zimulti, Rimonabant, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Acomplia

  • Rimonabant adds appetizing choice to slim obesity market [1].
  • Blood from haemorrhaged rats causes hypotension in normal rats, which can be prevented by SR141716A but not by inhibition of nitric oxide synthase in the recipient [2].
  • Treatment with the CB1 receptor antagonist SR141716A decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three models of chronic liver injury [3].
  • In support of this conclusion, the CB1 antagonist SR141716A enhances capsaicin-evoked bronchospasm and cough [4].
  • Modulation of the endogenous endocannabinoid system by rimonabant, which is under regulatory review, has been shown to improve body weight, atherogenic lipid profiles and glycaemic control [5].

Psychiatry related information on Acomplia


High impact information on Acomplia


Chemical compound and disease context of Acomplia

  • Recently, it has been shown that rimonabant prevents indomethacin-induced intestinal injury by decreasing the levels of pro-inflammatory cytokine tumour necrosis factor alpha (TNFalpha), thus indicating that CB1 receptor antagonists might exhibit potential anti-inflammatory activity in acute and chronic diseases [15].
  • Nevertheless, AM404 increases circulating anandamide levels and inhibits motor activity, an effect that is prevented by the CB1 cannabinoid antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A) [16].
  • The ACEA-induced suppression of mechanical and thermal hypersensitivity was blocked by local injection of SR141716A but not SR144528 [17].
  • The selective CB(1) antagonist, SR141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride] (5 and 10 mg/kg, i.m.), blocked the WIN 55212-2-induced hypothermia, suggesting that CB(1) receptor activation mediated the hypothermia [18].
  • The potential involvement of cannabinoid receptors (CB) was investigated by encephalitogenic T cell stimulation in the presence of the CB(1) (SR141716A) and CB(2) (SR144528) antagonists, pertussis toxin (PTX) and the inactive enantiomer WIN-3 [19].

Biological context of Acomplia

  • Here we report that a selective CB1 receptor antagonist, SR141716A, elicits an increase in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normotensive rats or intracerebroventricular administration of the antagonist during shock do not affect blood pressure [2].
  • Inhibitors of endocannabinoid inactivation enhance CaCo-2 cell endocannabinoid levels and block cell proliferation, this effect being antagonized by SR141716A [20].
  • The EC50 for stimulation of ERK phosphorylation was 10 nm, and this effect was blocked by pertussis toxin and the CB1 (cannabinoid) receptor antagonist SR141716A [21].
  • The effects of the cannabinoid-1 receptor (CB(1)) antagonist rimonabant on energy metabolism and fasting-induced hypothalamic-pituitary-adrenal (HPA) axis and neuronal activation were investigated [7].
  • Rimonabant also reduced plasma glucose, insulin, and homeostasis model assessment of insulin resistance, which further confirms the ability of CB(1) antagonists to improve insulin sensitivity [7].

Anatomical context of Acomplia

  • In a previous study, we have shown that macrophages activated by SR141716A, a ligand of the cannabinoid receptor CB1, acquired the capacity to control Brucella and observed that the CB1 receptor-triggering engages the microbicidal activity of phagocytes [22].
  • Rimonabant also exacerbated the neuronal activation seen in the arcuate nucleus (ARC) after short-term deprivation [7].
  • Findings that the CB1 selective antagonist/inverse agonist SR141716A produces in vivo and in vitro signs of increased motility of rodent small intestine probably reflect the presence in the enteric nervous system of a population of CB1 receptors that are precoupled to their effector mechanisms [23].
  • SR141716A has been reported not to behave in this manner in the myenteric plexus-longitudinal muscle preparation (MPLM) of human ileum unless this has first been rendered cannabinoid tolerant [23].
  • METHODS: The early effect of left coronary artery ligation on hemodynamic variables was measured in rats pretreated with the selective cannabinoid(1) receptor (CB(1)) antagonist SR141716A (herein referred to as SR, 6.45 micromol/kg body weight intravenously) or vehicle [24].

Associations of Acomplia with other chemical compounds

  • The selective CGRP-receptor antagonist 8-37 CGRP, but not the cannabinoid CB1 receptor blocker SR141716A, inhibited the vasodilator effect of anandamide [25].
  • In agreement with this possibility, the CB1 antagonist SR141716A and the CB2 antagonist SR144528 prolong and enhance the pain behaviour produced by tissue damage [26].
  • The high ethanol preference of young (6-10 weeks) C57BL6J mice is reduced by the cannabinoid receptor 1 (CB1) antagonist SR141716A to levels observed in their CB1 knockout littermates or in old (26-48 weeks) wild-type mice, in both of which ethanol preference is unaffected by SR141716A [27].
  • Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats [7].
  • These results support the hypothesis that hydrogen bonding of the SR141716A C3 substituent with K3.28 is responsible for its higher affinity for the inactive R state, leading to its inverse agonism [28].
  • In parallel, treatment of obese (fa/fa) rats with rimonabant reduced the high plasma level of the proinflammatory cytokine TNFalpha and increased the reduced plasma level of the anti-inflammatory hormone adiponectin [29].
  • Amelioration of insulin resistance in the ob/ob mice was attributed to the decrease of glucose production and activation of AMP-activated protein kinase (AMPK) in the liver induced by rimonabant but not to increased glucose uptake by the skeletal muscle [30].

Gene context of Acomplia

  • The cannabinoid CB1 receptor antagonist, SR141716A (0.1-100 nM), but not the cannabinoid CB2 receptor antagonist, SR144528 (0.1-100 nM), reduced in a dose-related manner WIN 55,212-2-and cannabinol-induced inhibition of nitrite production [31].
  • In both models the antihyperalgesic activity was prevented by the CB1-antagonist SR141716A but not the CB2-antagonist SR144528 [32].
  • Rats were habituated to the test environment and injection procedure and then received intracerebroventicular injections of various combinations of the MCR4 receptor antagonist JKC-363, the CB(1) receptor agonist Delta(9)-tetrahydrocannabinol, the MCR4 receptor agonist alpha-MSH, or the cannabinoid CB(1) receptor antagonist SR 141716 [33].
  • The effects of cannabinoids on p38-MAPK were mediated through activation of CB1-R because they were blocked in the presence of SR 141716 A and absent in CB1-R knockout mice, two conditions that did not alter the effects of LPA [34].
  • Treatment with SR141716A after chronic WIN55212-2 resulted in the expected cannabinoid withdrawal syndrome, without concomitant alterations in the phosphorylation state of c-Raf-1, MEK1/2, or ERK1/2 [35].

Analytical, diagnostic and therapeutic context of Acomplia

  • METHODS: These experiments aimed to investigate the effects of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in animal models measuring aspects of emotional reactivity and depression [36].
  • In particular, hypothermia, analgesia, and catalepsy induced by this endogenous ligand are not reversed by SR 141716 [8].
  • In preparations from LPS-pretreated rats, SR141716A alone caused a significant and prolonged increase in perfusion pressure, whereas it had no such effect in control preparations perfused in vitro with or without LPS or after endothelial denudation in preparations from rats pretreated with LPS [37].
  • The CB1 antagonist SR141716A potently and dose-dependently suppressed self-administration in AA rats when given systemically, or locally into the PFC, but not in the striatum [38].
  • Neonatal (6-day-old) rat pups received a systemic injection of a mixed CB(1) /CB(2) receptor agonist (WIN55,212-2) or their respective antagonists (SR141716A for CB(1) and SR144528 for CB(2) ) prior to an unilateral intrastriatal microinjection of NMDA [39].


  1. Rimonabant adds appetizing choice to slim obesity market. Wadman, M. Nat. Med. (2006) [Pubmed]
  2. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Wagner, J.A., Varga, K., Ellis, E.F., Rzigalinski, B.A., Martin, B.R., Kunos, G. Nature (1997) [Pubmed]
  3. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Teixeira-Clerc, F., Julien, B., Grenard, P., Tran Van Nhieu, J., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., Lotersztajn, S. Nat. Med. (2006) [Pubmed]
  4. Bidirectional control of airway responsiveness by endogenous cannabinoids. Calignano, A., Kátona, I., Désarnaud, F., Giuffrida, A., La Rana, G., Mackie, K., Freund, T.F., Piomelli, D. Nature (2000) [Pubmed]
  5. Diabetes: assessing the pipeline. Lebovitz, H. Atherosclerosis. Supplements. (2006) [Pubmed]
  6. Involvement of the endocannabinoid system in drug addiction. Maldonado, R., Valverde, O., Berrendero, F. Trends Neurosci. (2006) [Pubmed]
  7. Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats. Doyon, C., Denis, R.G., Baraboi, E.D., Samson, P., Lalonde, J., Deshaies, Y., Richard, D. Diabetes (2006) [Pubmed]
  8. Behavioral effects of cannabinoid agents in animals. Chaperon, F., Thiébot, M.H. Critical reviews in neurobiology. (1999) [Pubmed]
  9. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. López-Moreno, J.A., González-Cuevas, G., Navarro, M. Neurobiol. Dis. (2007) [Pubmed]
  10. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. Compton, D.R., Aceto, M.D., Lowe, J., Martin, B.R. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  11. The endogenous cannabinoid system controls extinction of aversive memories. Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., Di Marzo, V., Lutz, B. Nature (2002) [Pubmed]
  12. Leptin-regulated endocannabinoids are involved in maintaining food intake. Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G.I., Palmiter, R.D., Sugiura, T., Kunos, G. Nature (2001) [Pubmed]
  13. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Bátkai, S., Járai, Z., Wagner, J.A., Goparaju, S.K., Varga, K., Liu, J., Wang, L., Mirshahi, F., Khanolkar, A.D., Makriyannis, A., Urbaschek, R., Garcia, N., Sanyal, A.J., Kunos, G. Nat. Med. (2001) [Pubmed]
  14. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Huffman, J.W., Layward, L. Nature (2000) [Pubmed]
  15. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Tucci, S.A., Halford, J.C., Harrold, J.A., Kirkham, T.C. Current medicinal chemistry. (2006) [Pubmed]
  16. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Giuffrida, A., Beltramo, M., Piomelli, D. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  17. Activation of peripheral cannabinoid CB(1) and CB(2) receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Gutierrez, T., Farthing, J.N., Zvonok, A.M., Makriyannis, A., Hohmann, A.G. Br. J. Pharmacol. (2007) [Pubmed]
  18. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia. Rawls, S.M., Cabassa, J., Geller, E.B., Adler, M.W. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  19. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB(2) receptor. S??nchez, A.J., Gonz??lez-P??rez, P., Galve-Roperh, I., Garc??a-Merino, A. Biochem. Pharmacol. (2006) [Pubmed]
  20. Possible endocannabinoid control of colorectal cancer growth. Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M.G., Cosenza, V., D'argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., Di Marzo, V. Gastroenterology (2003) [Pubmed]
  21. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. Davis, M.I., Ronesi, J., Lovinger, D.M. J. Biol. Chem. (2003) [Pubmed]
  22. Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection. Gross, A., Bouaboula, M., Casellas, P., Liautard, J.P., Dornand, J. J. Immunol. (2003) [Pubmed]
  23. Cannabinoids and the gastrointestinal tract. Pertwee, R.G. Gut (2001) [Pubmed]
  24. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. Wagner, J.A., Hu, K., Bauersachs, J., Karcher, J., Wiesler, M., Goparaju, S.K., Kunos, G., Ertl, G. J. Am. Coll. Cardiol. (2001) [Pubmed]
  25. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D., Högestätt, E.D. Nature (1999) [Pubmed]
  26. Control of pain initiation by endogenous cannabinoids. Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D. Nature (1998) [Pubmed]
  27. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Wang, L., Liu, J., Harvey-White, J., Zimmer, A., Kunos, G. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  28. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Hurst, D.P., Lynch, D.L., Barnett-Norris, J., Hyatt, S.M., Seltzman, H.H., Zhong, M., Song, Z.H., Nie, J., Lewis, D., Reggio, P.H. Mol. Pharmacol. (2002) [Pubmed]
  29. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Gary-Bobo, M., Elachouri, G., Gallas, J.F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., Arnone, M., Croci, T., Soubrié, P., Oury-Donat, F., Maffrand, J.P., Scatton, B., Lacheretz, F., Le Fur, G., Herbert, J.M., Bensaid, M. Hepatology (2007) [Pubmed]
  30. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., Moroi, M., Sugi, K., Yamauchi, T., Noda, T., Nagai, R., Terauchi, Y., Tobe, K., Ueki, K., Kadowaki, T. J. Biol. Chem. (2009) [Pubmed]
  31. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. Esposito, G., Izzo, A.A., Di Rosa, M., Iuvone, T. J. Neurochem. (2001) [Pubmed]
  32. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Dyson, A., Peacock, M., Chen, A., Courade, J.P., Yaqoob, M., Groarke, A., Brain, C., Loong, Y., Fox, A. Pain (2005) [Pubmed]
  33. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Verty, A.N., McFarlane, J.R., McGregor, I.S., Mallet, P.E. Endocrinology (2004) [Pubmed]
  34. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. Derkinderen, P., Ledent, C., Parmentier, M., Girault, J.A. J. Neurochem. (2001) [Pubmed]
  35. Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: Short-term regulation by intrinsic and extrinsic pathways. Moranta, D., Esteban, S., García-Sevilla, J.A. J. Neurosci. Res. (2007) [Pubmed]
  36. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Griebel, G., Stemmelin, J., Scatton, B. Biol. Psychiatry (2005) [Pubmed]
  37. Mesenteric vasodilation mediated by endothelial anandamide receptors. Wagner, J.A., Varga, K., Járai, Z., Kunos, G. Hypertension (1999) [Pubmed]
  38. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Hansson, A.C., Berm??dez-Silva, F.J., Malinen, H., Hyyti??, P., Sanchez-Vera, I., Rimondini, R., Rodriguez de Fonseca, F., Kunos, G., Sommer, W.H., Heilig, M. Neuropsychopharmacology (2007) [Pubmed]
  39. Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. Hansen, H.H., Azcoitia, I., Pons, S., Romero, J., García-Segura, L.M., Ramos, J.A., Hansen, H.S., Fernández-Ruiz, J. J. Neurochem. (2002) [Pubmed]
WikiGenes - Universities